Skip to main content

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2345${count})

  • Rapid Response Innovation Awards, 2012
    Phosphorylated Alpha-synuclein Species as Biomarkers for Diagnosis and Progression in Parkinson’s disease

    Objective/Rationale:
    Diagnosis of Parkinson’s disease would be facilitated by the discovery of objective biomarkers for identifying it at early stages and differentiating it from other related...

  • MJFF Research Grant, 2012
    Using External Research Experts to Mine the 23andMe Parkinson’s Dataset

    Objective/Rationale:
    Currently at 23andMe we have whole-genome genotype data for 5,449 Parkinson’s disease (PD) patients and 110,853 healthy subjects. This is by far the largest cohort of case-control...

  • Therapeutics Development Initiative, 2012
    Targeting System-xc for the Treatment of Parkinson's Disease

    Objective/Rationale:
    Parkinson’s disease is characterized by the progressive loss of dopamine neurons in brain regions responsible for motor coordination and activity – disturbances of which are...

  • MJFF Research Grant, 2012
    Pharmacological Targeting of the 5-HT1, A2A and NMDA Receptors: An Integrative Approach to Dyskinesia

    Objective/Rationale:
    The glutamate, serotonin and adenosine systems are interesting targets for pharmacological therapies in Parkinson´s disease. However, interventions addressed at single systems...

  • Target Validation, 2012
    Validation of ATP13a2 / PARK9 as a Target to Reduce Neurodegeneration Induced by Alpha-Synuclein

    Objective/Rationale:
    Alpha-synuclein plays a prominent role in Parkinson’s disease and identifying valid targets to ameliorate the neurodegenerative effects of alpha-synuclein is a major therapeutic...

  • Clinical Intervention Awards, 2012
    Phase I Study of AAV2-hAADC Administered by MRI-guided Real-time Convective Infusion

    Objective/Rationale:
    The purpose of this study is to provide safety data related to enhancements in the clinical delivery procedure for administering Adeno-Associated Virus Encoding Human Aromatic L...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.